eISSN: 1644-4124
ISSN: 1426-3912
Central European Journal of Immunology
Current issue Archive Manuscripts accepted About the journal Special Issues Editorial board Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
4/2008
vol. 33
 
Share:
Share:
abstract:

Clinical immunology
PAI-1, fibrinogen, AT-III and angiogenic activity of plasma in patients before and 14 days after orthopaedic surgery and 14 daily enoxaparine injections

Adriana Roży
,
Leszek Jung
,
Joanna Chorostowska-Wynimko
,
Ewa Skopińska-Różewska
,
Ewa Sommer
,
Adamina Borowska
,
Bożena Wojciechowska
,
Adam Szpechciński
,
Barbara J. Bałan

Centr Eur J Immunol 2008; 33 (4): 224-227
Online publish date: 2008/12/24
View full text Get citation
 
We previously reported that single enoxaparine dose administered prior to the hip surgery resulted in an increase of angiogenic activity and basic fibroblast growth factor (bFGF) level in patients’ sera without any corresponding alterations in the vascular endothelial growth factor (VEGF) concentration. Increased VEGF serum level, however, was observed in sera after 14 enoxaparine injections. Plasminogen activator inhibitor-1 (PAI-1) levels increased after single enoxaparine dose, and no significant alterations in plasma VEGF, fibrinogen and antithrombin III (AT-III) levels were seen. In the present paper we have study the same parameters in plasma of patients treated with enoxaparine for 2 weeks after surgery.
Significant increase of plasma PAI-1 and fibrinogen concentration, as well as angiogenic plasma activity in vivo in PIA mice cutaneous test, were observed. No alterations in plasma VEGF and AT-III were seen.
keywords:

plasma, enoxaparine, angiogenesis, VEGF, PAI-1, fibrinogen, AT-III

Quick links
© 2024 Termedia Sp. z o.o.
Developed by Bentus.